DGAP-News: WILEX AG reports on Annual General Meeting 2012
(firmenpresse) - DGAP-News: WILEX AG / Key word(s): AGM/EGM
WILEX AG reports on Annual General Meeting 2012
25.05.2012 / 23:51
---------------------------------------------------------------------
PRESS RELEASE
WILEX reports on Annual General Meeting 2012
- Dr Birgit Kudlek elected as new member of the Supervisory Board
- FDA confirms Advisory Committee meeting
Munich, Germany, 25 May 2012. WILEX AG (ISIN DE0006614720 / WL6 / FWB)
today announced that the Company's ordinary Annual General Meeting has
elected Dr Birgit Kudlek as a new member of the Supervisory Board. Dr
Kudlek succeeds Dr Alexandra Goll, who stepped down from the Supervisory
Board effective December 2011.
'We are pleased to have Dr Kudlek as a further member of the Supervisory
Board with excellent industry knowledge and experience in the development
and manufacturing of pharmaceutical products' commented Professor Christof
Hettich, Chairman of WILEX AG's Supervisory Board.
The shareholders of WILEX AG approved all management proposals put to vote
at the meeting with a large majority including:
- Formal approval of the activities of the members of the Executive
Management Board and the members of the Supervisory Board
- Election of Deloitte&Touche GmbH Wirtschaftsprüfungsgesellschaft to
serve as the auditor of the annual financial statements for the
2011/2012 financial year
- Resolution to revoke the existing Authorised Capital 2010/II and create
new Authorised Capital 2012/I as well as to amend the Articles of
Association correspondingly
At the Annual General Meeting of WILEX AG 73.34% of the voting shares were
represented.
At the meeting WILEX presented the current status of the clinical trials.
The Company had previously informed its shareholders that the FDA proposed
using an Advisory Committee to review the development strategy for
REDECTANE(R). The FDA has now confirmed that the Oncologic Drugs Advisory
Committee (ODAC), scheduled for the 25th July 2012, will be the forum for
this discussion. The ODAC will be asked to discuss and provide general
advice on the extent to which, if any, the pre-surgical identification of
clear cell carcinoma of the kidney using an imaging test provides useful
clinical information.
All information regarding the Annual General Meeting is published on the
Company's website:
http://www.wilex.de/press-investors/annual-general-meeting/agm2012/
Contact
WILEX AG
Katja Arnold (CIRO)
Grillparzerstrasse 10
81675 Munich, Germany
Tel.: +49 (0)89-41 31 38-126
Fax: +49 (0)89-41 31 38-99
E-mail: investors [at] wilex.com
About WILEX
WILEX AG is a biopharmaceutical company based in Munich, Germany. Focused
on oncology, the Company has a broad portfolio of diagnostic and
therapeutic products for the specific detection and targeted treatment of
various types of cancer. WILEX's therapeutic product candidates are based
on antibodies (RENCAREX(R) in Phase III) and small molecules (MESUPRON(R)
in Phase II, WX-554 in Phase Ib/II and WX-037 in preclinical development).
In the field of diagnostics, REDECTANE(R) is an antibody-based, imaging in
vivo diagnostic agent that is currently in a Phase III programme. WILEX's
US subsidiary WILEX Inc. in Cambridge, MA, markets a portfolio of research
use only tests and in vitro diagnostic agents under the brand Oncogene
Science, which are used as companion diagnostics for clinical trials and
therapy monitoring. The wholly owned subsidiary Heidelberg Pharma GmbH
offers an attractive and highly promising antibody drug conjugate
technology platform and preclinical contract research services. The
business model of WILEX comprises research, technology, product development
and commercialisation. WILEX's customers and partners include leading
international pharmaceutical companies.
Website: http://www.WILEX.com, ISIN DE0006614720 / WKN 661472 / Symbol WL6
This communication contains certain forward-looking statements relating to
the Company's business, which can be identified by the use of
forward-looking terminology such as 'estimates', 'believes', 'expects',
'may', 'will', 'should', 'future', 'potential' or similar expressions or by
a general discussion of the Company's strategy, plans or intentions. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause our actual results of operations,
financial position, earnings, achievements, or industry results, to be
materially different from any future results, earnings or achievements
expressed or implied by such forward-looking statements. Given these
uncertainties, prospective investors and partners are cautioned not to
place undue reliance on such forward-looking statements. We disclaim any
obligation to update any such forward-looking statements to reflect future
events or developments.
End of Corporate News
---------------------------------------------------------------------
25.05.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: WILEX AG
Grillparzerstr. 10
81675 München
Germany
Phone: +49 (0)89 41 31 38 - 0
Fax: +49 (0)89 41 31 38 - 99
E-mail: info(at)wilex.com
Internet: www.wilex.com
ISIN: DE0006614720
WKN: 661472
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
171665 25.05.2012
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 25.05.2012 - 23:51 Uhr
Sprache: Deutsch
News-ID 150340
Anzahl Zeichen: 7716
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 435 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: WILEX AG reports on Annual General Meeting 2012"
steht unter der journalistisch-redaktionellen Verantwortung von
WILEX AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
